biologic

Opdivo

nivolumab

Loss of exclusivityDecember 2026projected — 12-year biologic exclusivity estimate
CompanyBristol-Myers Squibb CompanyView the full company profile on CliffBio

Drug detail

Brand nameOpdivo
Active ingredientnivolumab
Strength100MG/10ML (10MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalDecember 2014
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Opdivo patent cliff — loss of exclusivity December 2026 | CliffBio